Characterization of Patients With Advanced Pancreatic Cancer and High Serum Interleukin-6 Levels

Pancreas

Volumn 44, Issue 5, 2015, Pages 756-763

  Miura, Tomofumi ^a   Mitsunaga, Shuichi ^a   Ikeda, Masafumi ^a   Shimizu, Satoshi ^a   Ohno, Izumi ^a   Takahashi, Hideaki ^a   Furuse, Junji ^b   Inagaki, Masatoshi ^c   Higashi, Sayumi ^d   Kato, Hiroyuki ^d   Terao, Kimio ^d   Ochiai, Atsushi ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^d CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

anti IL 6 therapy; cancer cachexia; interleukin 6; pancreatic cancer

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; AXITINIB; C REACTIVE PROTEIN; CA 19-9 ANTIGEN; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; HEMOGLOBIN; INTERLEUKIN 6; IL6 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASCITES; BILIARY TRACT DRAINAGE; BODY COMPOSITION; BODY MASS; BODY WEIGHT; CACHEXIA; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER PATIENT; CANCER SIZE; CANCER STAGING; FEMALE; HUMAN; KARNOFSKY PERFORMANCE STATUS; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MONOTHERAPY; MUSCLE MASS; NEUTROPHIL; PANCREAS CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; SKELETAL MUSCLE; TERMINALLY ILL PATIENT; WEIGHT REDUCTION; AGE; BLOOD; CHI SQUARE DISTRIBUTION; COMPLICATION; FATIGUE; LIVER TUMOR; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREATIC NEOPLASMS; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; SECONDARY; STATISTICAL MODEL; TUMOR VOLUME; UPREGULATION; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANEMIA; BIOMARKERS, TUMOR; BODY COMPOSITION; C-REACTIVE PROTEIN; CACHEXIA; CARCINOEMBRYONIC ANTIGEN; CHI-SQUARE DISTRIBUTION; FATIGUE; FEMALE; HUMANS; INTERLEUKIN-6; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREATIC NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; TUMOR BURDEN; UP-REGULATION;

EID: 84932635849     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0000000000000335     Document Type: Article

References (39)

1. Martignoni ME, Kunze P, Hildebrandt W, et al. Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexia. Clin Cancer Res. 2005;11:5802-5808.
2. Stouthard JM, Goey H, de Vries EG, et al. Recombinant human interleukin 6 in metastatic renal cell cancer: a phase II trial. Br J Cancer. 1996;73:789-793.
3. van Hall G, Steensberg A, Fischer C, et al. Interleukin-6 markedly decreases skeletal muscle protein turnover and increases nonmuscle amino acid utilization in healthy individuals. J Clin Endocrinol Metab. 2008;93:2851-2858.
4. van Hall G, Steensberg A, Sacchetti M, et al. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab. 2003;88:3005-3010.
5. Okada S, Okusaka T, Ishii H, et al. Elevated serum interleukin-6 levels in patients with pancreatic cancer. Jpn J Clin Oncol. 1998;28:12-15.
6. Ebrahimi B, Tucker SL, Li D, et al. Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer. 2004;101:2727-2736.
7. Talar-Wojnarowska R, Gasiorowska A, Smolarz B, et al. Clinical significance of interleukin-6 (IL-6) gene polymorphism and IL-6 serum level in pancreatic adenocarcinoma and chronic pancreatitis. Dig Dis Sci. 2009;54:683-689.
8. Wenger FA, Jacobi CA, Zieren J, et al. Tumor size and lymph-node status in pancreatic carcinoma - is there a correlation to the preoperative immune function? Langenbecks Arch Surg. 1999;384:473-478.
9. Roxburgh CS, McMillan DC. Cancer and systemic inflammation: treat the tumour and treat the host. Br J Cancer. 2014;110:1409-1412.
10. Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106:2627-2632.
11. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
12. Mitsunaga S, Ikeda M, Shimizu Y, et al. Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer. 2013;108:2063-2069.
13. Padillo FJ, Muntane J, Montero JL, et al. Effect of internal biliary drainage on plasma levels of endotoxin, cytokines, and C-reactive protein in patients with obstructive jaundice. World J Surg. 2002;26:1328-1332.
14. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
15. Inagaki M, Isono M, Okuyama T, et al. Plasma interleukin-6 and fatigue in terminally ill cancer patients. J Pain Symptom Manage. 2008;35:153-161.
16. Okuyama T, Wang XS, Akechi T, et al. Validation study of the Japanese version of the brief fatigue inventory. J Pain Symptom Manage. 2003;25:106-117.
17. Zhang GJ, Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res. 1999;19:1427-1432.
18. Ueda T, Shimada E, Urakawa T. Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis. J Gastroenterol. 1994;29:423-429.
19. Yoshikawa K, Mitsunaga S, Kinoshita T, et al. Impact of tumor-associated macrophages on invasive ductal carcinoma of the pancreas head. Cancer Sci. 2012;103:2012-2020.
20. Benson DD, Meng X, Fullerton DA, et al. Activation state of stromal inflammatory cells in murine metastatic pancreatic adenocarcinoma. Am J Physiol Regul Integr Comp Physiol. 2012;302:R1067-R1075.
21. Thomas P, Forse RA, Bajenova O. Carcinoembryonic antigen (CEA) and its receptor hnRNP M are mediators of metastasis and the inflammatory response in the liver. Clin Exp Metastasis. 2011;28:923-932.
22. Paschos KA, Canovas D, Bird NC. The role of cell adhesion molecules in the progression of colorectal cancer and the development of liver metastasis. Cell Signal. 2009;21:665-674.
23. Rooyackers OE, Adey DB, Ades PA, et al. Effect of age on in vivo rates of mitochondrial protein synthesis in human skeletal muscle. Proc Natl Acad Sci U S A. 1996;93:15364-15369.
24. Ogiwara H, Takahashi S, Kato Y, et al. Diminished visceral adipose tissue in cancer cachexia. J Surg Oncol. 1994;57:129-133.
25. Ebisui C, Tsujinaka T, Morimoto T, et al. Interleukin-6 induces proteolysis by activating intracellular proteases (cathepsins B and L, proteasome) in C2C12 myotubes. Clin Sci (Lond). 1995;89:431-439.
26. Krishnan S, Rana V, Janjan NA, et al. Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer. 2006;107:2589-2596.
27. Holly EA, Chaliha I, Bracci PM, et al. Signs and symptoms of pancreatic cancer: a population-based case-control study in the San Francisco Bay area. Clin Gastroenterol Hepatol. 2004;2:510-517.
28. Wigmore SJ, Plester CE, Richardson RA, et al. Changes in nutritional status associated with unresectable pancreatic cancer. Br J Cancer. 1997;75:106-109.
29. Bye A, Jordhoy MS, Skjegstad G, et al. Symptoms in advanced pancreatic cancer are of importance for energy intake. Support Care Cancer. 2013;21:219-227.
30. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines: Cancer-Related Fatigue - v.1.2013. Available at http://www.nccn.org/professionals/physician-gls/f-guidelines.asp. Accessed September 19, 2013.
31. Panju AH, Danesh A, Minden MD, et al. Associations between quality of life, fatigue, and cytokine levels in patients aged 50+ with acute myeloid leukemia. Support Care Cancer. 2009;17:539-546.
32. Wang XS, Shi Q, Williams LA, et al. Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav Immun. 2010;24:968-974.
33. Wang XS, Williams LA, Krishnan S, et al. Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy. Brain Behav Immun. 2012;26:699-705.
34. Castell JV, Gomez-Lechon MJ, David M, et al. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990;12:1179-1186.
35. Wigmore SJ, Fearon KC, Maingay JP, et al. Interleukin-8 can mediate acute-phase protein production by isolated human hepatocytes. Am J Physiol. 1997;273:E720-E726.
36. Ganz T, Nemeth E. Hepcidin and disorders of iron metabolism. Annu Rev Med. 2011;62:347-360.
37. Sun CC, Vaja V, Babitt JL, et al. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol. 2012;87:392-400.
38. Kemna E, Pickkers P, Nemeth E, et al. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood. 2005;106:1864-1866.
39. Huang H, Constante M, Layoun A, et al. Contribution of STAT3 and SMAD4 pathways to the regulation of hepcidin by opposing stimuli. Blood. 2009;113:3593-3599.